Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus

Neurobiology of Disease

Volumn 37, Issue 1, 2010, Pages 67-76

  Valente, Tony ^a   Gella, Alejandro ^b   Fernàndez Busquets, Xavier ^c   Unzeta, Mercedes ^a   Durany, Nuria ^b  

^a Institute of Neuroscience   (Spain)

^b UNIVERSITAT INTERNACIONAL DE CATALUNYA   (Spain)

^c INSTITUTE FOR BIOENGINEERING OF CATALONIA IBEC   (Spain)

Author keywords

Abeta; AGEs; Alzheimer's disease; Diabetes; Immunohistochemistry; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROGLIA; NERVE CELL LESION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN AGGREGATION; SENILE PLAQUE;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BRAIN; CELL COUNT; DIABETES MELLITUS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROGLIA; MIDDLE AGED; PEPTIDE FRAGMENTS; PLANT LECTINS; RECEPTORS, IMMUNOLOGIC; SENILE PLAQUES; TAU PROTEINS; THIAZOLES;

EID: 70449732132     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2009.09.008     Document Type: Article

References (80)

1. Ahmed N. Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Res. Clin. Pract. 67 (2005) 3-21
2. Akama K.T., Albanese C., Pestell R.G., and Van Eldik L.J. Amyloid beta-peptide stimulates nitric oxide production in astrocytes through an NKkappaB-dependent mechanism. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 5795-5800
3. 1-42 fibrillogenesis with atomic force microscopy. FASEB J. 19 (2005) 1344-1346
4. Arvanitakis Z., Wilson R.S., Bienias J.L., Evans D.A., and Bennett D.A. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch. Neurol. 61 (2004) 661-666
5. Bales K.R., Du Y., Dodel R.C., Yan M., Hamilton-Byrd E., and Paul S.M. The NF-kappaB/Rel family of proteins mediates Abeta-induced neurotoxicity and glial activation. Mol. Brain Res. 57 (1998) 63-72
6. Baynes J.W. Role of oxidative stress in development of complications in diabetes. Diabetes 40 (1991) 405-412
7. Becker A.J., Gillardon F., Blumcke I., Langendorfer D., Beck H., and Wiestler O.D. Differential regulation of apoptosis-related genes in resistant and vulnerable subfields of the rat epileptic hippocampus. Mol. Brain Res. 67 (1999) 172-176
8. Braak H., and Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82 (1991) 239-259
9. Brands A.M., Kessels R.P., de Haan E.H., Kappelle L.J., and Biessels G.J. Cerebral dysfunction in type 1 diabetes: effects of insulin, vascular risk factors and blood-glucose levels. Eur. J. Pharmacol. 19 (2004) 159-168
10. 1-42 peptide into stable fibrils of reduced cytotoxicity. J. Biol. Chem. 283 (2008) 32471-32483
11. Brookmeyer R., Gray S., and Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am. J. Public 88 (1998) 1337-1342
12. Brownlee M., Vlassara H., and Cerami A. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann. Intern. Med. 101 (1984) 527-537
13. Carro E., and Torres-Aleman I. The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. Eur. J. Pharmacol. 490 (2004) 127-133
14. Catalano S.M., Dodson E.C., Henze D.A., Joyce J.G., Krafft G.A., and Kinney G.G. The role of amyloid-β derived diffusible ligands (ADDLs) in Alzheimer's disease. Curr. Top. Med. Chem. 6 (2006) 597-608
15. Chen X., Walker D.G., Schmidt A.M., Arancio O., Lue L.F., and Yan S.D. RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease. Curr. Mol. Med. 7 (2007) 735-742
16. Crystal H., Dickson D., Fuld P., Masur D., Scott R., Mehler M., Masdeu J., Kawas C., Aronson M., and Wolfson L. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 11 (1988) 1682-1687
17. de la Monte S.M., and Wands J.R. Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. J. Alzheimers Dis. 9 (2006) 167-181
18. Dickson D.W., Crystal H.A., Mattiace L.A., Masur D.M., Blau A.D., Davies P., Yen S.H., and Aronson M.K. Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol. Aging 13 (1992) 179-189
19. Djebaïli M., Lerner-Natoli M., Pascale M., Baille V., Bockaert J., and Rondouin G. Molecular events involved in neuronal death induced in the mouse hippocampus by in-vivo injection of kainic acid. Mol. Brain Res. 93 (2001) 190-198
20. Doble B.W., and Woodgett J.R. GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. 116 (2003) 1175-1186
21. Dukic-Stefanovic S., Schinzel R., Riederer P., and Münch G. AGES in brain ageing: AGE-inhibitors as neuroprotective and anti-dementia drugs?. Biogerontology 2 (2001) 19-34
22. Durany N., Münch G., Michel T., and Riederer P. Investigations on oxidative stress and therapeutical implications in dementia. Eur. Arch. Psychiatry Clin. Neurosci. 249 (1999) 68-73
23. Gasic-Milenkovic J., Loske C., and Munch G. Advanced glycation endproducts cause lipid peroxidation in the human neuronal cell line SH-SY5Y. J. Alzheimer's Dis. 5 (2003) 25-30
24. Gella A., and Durany N. Oxidative stress in Alzheimer's disease. Cell Adh. Migr. 3 (2009) 88-93
25. Girones X., Guimera A., Cruz-Sanchez C.Z., Ortega A., Sasaki N., Makita Z., Lafuente J.V., Kalaria R., and Cruz-Sanchez F.F. N-epsilon-carboxymethyllysine in brain aging, diabetes mellitus, and Alzheimer's disease. Free Radic. Biol. Med. 36 (2004) 1241-1247
26. Guix F.X., Ill-Raga G., Bravo R., Nakaya T., Fabritiis G., Coma M., Miscione G.P., Villà-Freixa J., Suzuki T., Fernàndez-Busquets X., Valverde M.A., Strooper B., and Muñoz F.J. Amyloid-dependent triosephosphate isomerise nitrotyrosination induces glycation and tau fibrillation. Brain 132 (2009) 1335-1345
27. Haan M.N. Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease. Nat. Clin. Pract. Neurol. 2 (2006) 159-166
28. Heese K., and Akatsu H. Alzheimer's disease-an interactive perspective. Curr. Alzheimer Res. 3 (2006) 109-121
29. Hirata-Fukae C., Li H.F., Hoe H.S., Gray A.J., Minami S.S., Hamada K., Niikura T., Hua F., Tsukagoshi-Nagai H., Horikoshi-Sakuraba Y., Mughal M., Rebeck G.W., LaFerla F.M., Mattson M.P., Iwata N., Saido T.C., Klein W.L., Duff K.E., Aisen P.S., and Matsuoka Y. Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res. 24 (2008) 92-103
30. Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur. J. Pharmacol. 490 (2004) 115-125
31. Hy L.X., and Keller D.M. Prevalence of AD among whites: a summary by levels of severity. Neurology 55 (2000) 198-204
32. Kar S., Slowikowski S.P., Westaway D., and Mount H.T. Interactions between β-amyloid and central cholinergic neurons: implications for Alzheimer's disease. J. Psychiatry Neurosci. 29 (2004) 427-441
33. Kimura T., Takamatsu J., Araki N., Goto M., Kondo A., Miyakawa T., and Horiuchi S. Are advanced glycation end-products associated with amyloidosis in Alzheimer's disease?. Neuroreport 6 (1995) 866-868
34. Krebs M.R., Bromley E.H., and Donald A.M. The binding of thioflavin-T to amyloid fibrils: localisation and implications. J. Struct. Biol. 149 (2005) 30-37
35. Kuhla B., Loske C., Garcia de Arriba S., Schinzel R., Huber J., and Münch G. Differential effects of "advanced glycation endproducts" and β-amyloid peptide on glucose utilization and ATP levels in the neuronal cell line SH-SY5Y. J. Neural. Transm. 111 (2004) 427-439
36. LaFerla F.M., and Oddo S. Alzheimer's disease: Aβ, tau and synaptic dysfunction. Trends Mol. Med. 11 (2005) 170-176
37. LeVine H. Thioflavine, T interaction with synthetic Alzheimer's disease β-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 2 (1993) 404-410
38. Li J.J., Voisin D., Quiquerez A.L., and Bouras C. Differential expression of advanced glycosylation end-products in neurons of different species. Brain Res. 641 (1994) 285-288
39. Li Z.G., Zhang W., and Sima A.A. Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes 56 (2007) 1817-1824
40. Loske C., Gerdemann A., Schepl W., Wycislo M., Schinzel R., Palm D., Riederer P., and Munch G. Transition metal-mediated glycoxidation accelerates cross-linking of β-amyloid peptide. Eur. J. Biochem. 267 (2000) 4171-4178
41. Luchsinger J.A., Tang M.X., Shea S., and Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 12 63 (2004) 1187-1192
42. Lue L.F., Walker D.G., Brachova L., Beach T.G., Rogers J., Schmidt A.M., Stern D.M., and Yan S.D. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp. Neurol. 171 (2001) 29-45
43. Maczurek A., Shanmugam K., and Münch G. Inflammation and the redox-sensitive AGE-RAGE pathway as a therapeutic target in Alzheimer's disease. Ann. N.Y. Acad. Sci. 1126 (2008) 147-151
44. Mattson M.P., Carney J.W., and Butterfield D.A. A tombstone in Alzheimer's?. Nature 373 (1995) 481
45. Meredith S.C. Protein denaturation and aggregation: cellular responses to denatured and aggregated proteins. Ann. N.Y. Acad. Sci. 1066 (2005) 181-221
46. Monnier V.M., and Cerami A. Non-enzymatic glycosylation and browning of proteins in diabetes. Clin. Endocrinol. Metab. 11 (1982) 431-452
47. Mott R.T., and Hulette C.M. Neuropathology of Alzheimer's disease. Neuroimaging Clin. N. Am. 15 (2005) 755-765
48. Münch G., Deuther-Conrad W., and Gasic-Milenkovic J. Glycoxidative stress creates a vicious cycle of neurodegeneration in Alzheimer's disease-a target for neuroprotective treatment strategies?. J. Neural. Transm. Suppl. 62 (2002) 303-307
49. Münch G., Gasic-Milenkovic J., and Arendt T. Effect of advanced glycation endproducts on cell cycle and their relevance for Alzheimer's disease. J. Neural. Transm. Suppl. 65 (2003) 63-71
50. Münch G., Mayer S., Michaelis J., Hipkiss A.R., Riederer P., Muller R., Neumann A., Schinzel R., and Cunningham A.M. Influence of advanced glycation endproducts and AGE-inhibitors on nucleation-dependent polymerization of β-amyloid peptide. Biochim. Biophys. Acta 1360 (1997) 17-29
51. Münch G., Schinzel R., Loske C., Wong A., Durany N., Li J.J., Vlassara H., Smith M.A., Perry G., and Riederer P. Alzheimer's disease-synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J. Neural. Transm. 105 (1998) 439-461
52. Münch G., Thome J., Foley P., Schinzel R., and Riederer P. Advanced glycation endproducts in ageing and Alzheimer's disease. Brain Res. Brain Res. Rev. 23 (1997) 134-143
53. Origlia N., Righi M., Capsoni S., Cattaneo A., Fang F., Stern D.M., Chen J.X., Schmidt A.M., Arancio O., Yan S.D., and Domenici L. Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction. J. Neurosci. 28 (2008) 3521-3530
54. Overmyer M., Helisalmi S., Soininen H., Laakso M., Paavo R.S., and Alafuzoff I. Reactive microglia in aging and dementia: an immunohistochemical study of postmortem human brain tissue. Acta Neuropathol. 97 (1999) 383-392
55. Picklo M.J., Montine T.J., Amarnath V., and Neely M.D. Carbonyl toxicology and Alzheimer's disease. Toxicol. Appl. Pharmacol. 184 (2002) 187-197
56. Pollard H., Charriaut-Marlangue C., Cantagrel S., Represa A., Robain O., Moreau J., and Ben-Ari Y. Kainate-induced apoptotic cell death in hippocampal neurons. Neuroscience 63 (1994) 7-18
57. Prabhakaram M., and Ortwerth B.J. Determination of glycation crosslinking by the sugar-dependent incorporation of [14C]lysine into protein. Anal. Biochem. 216 (1994) 305-312
58. Qiu W.Q., and Folstein M.F. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiol. Aging 27 (2005) 190-198
59. Richter T., Munch G., Luth H.J., Arendt T., Kientsch-Engel R., Stahl P., Fengler D., and Kuhla B. Immunochemical crossreactivity of antibodies specific for "advanced glycation endproducts" with "advanced lipoxidation endproducts". Neurobiol. Aging 26 (2005) 465-474
60. Ristow M. Neurodegenerative disorders associated with diabetes mellitus. J. Mol. Med. 82 (2004) 510-529
61. Sasaki N., Fukatsu R., Tsuzuki K., Hayashi Y., Yoshida T., Fujii N., Koike T., Wakayama I., Yanagihara R., Garruto R., Amano N., and Makita Z. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am. J. Pathol. 153 (1998) 1149-1155
62. Sasaki N., Toki S., Chowei H., Saito T., Nakano N., Hayashi Y., Takeuchi M., and Makita Z. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res. 888 (2001) 256-262
63. Schmidt A.M., Yan S.D., Wautier J.L., and Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ. Res. 84 (1999) 489-497
64. Serpell L.C. Alzheimer's amyloid fibrils: structure and assembly. Biochim. Biophys. Acta 1502 (2000) 16-30
65. Smith M.A., Dunbar C.E., Miller E.J., and Perry G. Trypsin interaction with the senile plaques of Alzheimer disease is mediated by β-protein precursor. Mol. Chem. Neuropathol. 27 (1996) 145-154
66. Smith M.A., Sayre L.M., Monnier V.M., and Perry G. Radical AGEing in Alzheimer's disease. Trends Neurosci. 18 (1995) 172-176
67. Smith M.A., Taneda S., Richey P.L., Miyata S., Yan S.D., Stern D., Sayre L.M., Monnier V.M., and Perry G. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc. Natl. Acad. Sci. U. S. A 91 (1994) 5710-5714
68. Stern D., Yan S.D., Yan S.F., and Schmidt A.M. Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv. Drug Deliv. Rev. 54 (2002) 1615-1625
69. Takeuchi M., and Yamagishi S. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. Curr. Pharm. Des. 14 (2008) 973-978
70. Thome J., Münch G., Müller R., Schinzel R., Kornhuber J., Blum-Degen D., Sitzmann L., Rösler M., Heidland A., and Riederer P. Advanced glycation endproducts-associated parameters in the peripheral blood of patients with Alzheimer's disease. Life Sci. 59 (1996) 679-685
71. Troncoso J.C., Martin L.J., Dal Forno G., and Kawas C.H. Neuropathology in controls and demented subjects from the Baltimore Longitudinal Study of Aging. Neurobiol. Aging 17 (1996) 365-371
72. Vitek M.P., Bhattacharya K., Glendening J.M., Stopa E., Vlassara H., Bucala R., Manogue K., and Cerami A. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 4766-4770
73. Vlassara H., Bucala R., and Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab. Invest. 70 (1994) 138-151
74. Walker D.G., Kim S.U., and McGeer P.L. Complement and cytokine gene expression in cultured microglia derived from post-mortem human brains. J. Neurosci. Res. 40 (1995) 478-493
75. Walsh D.M., and Selkoe D.J. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept. Lett. 11 (2004) 213-228
76. Walsh D.M., Hartley D.M., Kusumoto Y., Fezoui Y., Condron M.M., Lomakin A., Benedek G.B., Selkoe D.J., and Teplow D.B. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J. Biol. Chem. 274 (1999) 25945-25952
77. Wells-Knecht K.J., Zyzak D.V., Litchfield J.E., Thorpe S.R., and Baynes J.W. Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry 34 (1995) 3702-3709
78. Yamagishi S., Matsui T., and Nakamura K. Blockade of the advanced glycation end products (AGEs) and their receptor (RAGE) system is a possible mechanism for sustained beneficial effects of multifactorial intervention on mortality in type 2 diabetes. Medical Hypotheses 71 (2008) 749-751
79. Yan S.D., Zhu H., Fu J., Yan S.F., Roher A., Tourtellotte W.W., Rajavashisth T., Chen X., Godman G.C., Stern D., and Schmidt A.M. Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 5296-5301
80. Yan S.F., Ramasamy R., and Schmidt A.M. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat. Clin. Pract. Endocrinol. Metab. 4 (2008) 285-293